Molecular Therapy-Oncolytics

Papers
(The TQCC of Molecular Therapy-Oncolytics is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Ferroptosis gene signature in cholangiocarcinoma246
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence79
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models55
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis50
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 146
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation43
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma39
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML36
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy36
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers36
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity33
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer33
PROTACs in gastrointestinal cancers33
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer33
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response32
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity32
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy30
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia30
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme30
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T29
A library of cancer testis specific T cell receptors for T cell receptor gene therapy29
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia28
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges27
Radiovirotherapy at twenty27
Adding recombinant AAVs to the cancer therapeutics mix26
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products26
Human lung adenocarcinoma CD47 is upregulated by interferon-γ and promotes tumor metastasis25
Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression25
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum25
Oncolytic adenovirus for treatment of malignant ascites24
The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?24
DNA-damaging cancer cells to improve virotherapy23
Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene23
ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma23
Thank you to our 2023 reviewers23
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice23
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis22
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities22
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells22
Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers21
An epitope encoded by uORF of RNF10 elicits a therapeutic anti-tumor immune response21
Non-coding RNAs and glioma: Focus on cancer stem cells21
Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution20
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon20
Sodium iodide symporter-targeted gene therapy in glioblastoma20
Purple sweet potato delphinidin-3-rutin represses glioma proliferation by inducing miR-20b-5p/Atg7-dependent cytostatic autophagy20
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape20
A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering20
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo20
0.44874596595764